A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

2021-02-11T23:49:39+00:00August 25th, 2018|2018 Publications, Featured Publications, Publications|

VIEW PUBLICATION ⟶